The BRN.AX stock moved higher intraday to A$0.14, up 3.70% on the ASX on 06 Mar 2026 as the market reacts to near-term earnings and edge-AI demand signals. Volume at 3,984,538 shares is below the 50-day average but jumped from the open of A$0.135. Investors are watching BrainChip Holdings Ltd (BRN.AX) for proof of commercial traction for its Akida neuromorphic chips and for any revenue lift from recent partnerships and the 04 Mar 2026 earnings announcement.

BRN.AX stock intraday snapshot

Intraday BRN.AX stock action shows a price range of A$0.13–A$0.142 with the last print at A$0.14 and a daily gain of 3.70%. Market cap sits near A$330.18M and shares outstanding are 2,358,458,279. The 50-day average price is A$0.16 and the 200-day average is A$0.19, which frames current trading as below medium and long-term trend levels. The stock opened at A$0.135 and the previous close was A$0.135, linking today’s move to intraday buying rather than a gap.

Fundamentals and financials for BrainChip Holdings Ltd

BrainChip (BRN.AX) reports an EPS of -0.01 and a trailing PE of -14.00, reflecting negative earnings. Key ratios show a price-to-book of 6.89 and price-to-sales near 121.55, signalling a valuation premium versus revenue. Cash per share stands at A$0.01 and current ratio is strong at 11.40, which indicates liquidity. Revenue growth for FY2025 was 3.91%, while R&D expense rose 13.87%, prioritising product development for edge AI applications.

Technical setup and trading indicators

Technically, BRN.AX shows neutral momentum with RSI at 46.77 and MACD near -0.01, suggesting no strong trend in price momentum. ADX at 32.12 indicates a measurable trend strength, but moving averages slope down. Average volume is 8,560,969 versus today’s 3,984,538, so liquidity is lighter intraday. Bollinger bands sit roughly A$0.13–A$0.15, so a breakout above A$0.15 would widen the near-term technical range.

Meyka AI grade and model forecast

Meyka AI rates BRN.AX with a score out of 100: 68.94 / 100 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of A$0.12, a 12-month projection of A$0.13594, and a 3-year projection of A$0.05484. Compared with the current price of A$0.14, the 12-month model implies a downside of about -2.90% and the monthly model implies -14.29%. Forecasts are model-based projections and not guarantees.

Catalysts, risks and sector context

Primary catalysts include commercial wins for the Akida neuromorphic processor, new OEM design wins, and follow-through from the 04 Mar 2026 earnings release. Key risks are ongoing negative earnings, high price-to-sales multiples, and slower-than-expected adoption in automotive or security markets. In the broader Technology sector on the ASX, software and semiconductor peers trade at higher PS ratios and stronger ROE, which places pressure on BRN.AX valuation until revenue scales.

Price targets, valuation view and trading strategy

Analyst-style price targets for trading frames: short-term target A$0.16 (implied +14.29%), medium-term target A$0.20 (+42.86%), and downside risk to A$0.08 (-42.86%) if adoption stalls. Valuation metrics—P/S ~121.55 and P/B ~6.89—require revenue growth to justify multiples. For traders, a disciplined approach is to watch a confirmed close above A$0.16 for momentum and maintain tight stops given volatility and thin average liquidity.

Final Thoughts

BRN.AX stock is trading at A$0.14 intraday on 06 Mar 2026, reflecting short-term interest following recent earnings and edge-AI headlines. Fundamentals show negative EPS (-0.01) and valuation stretched by high P/S and P/B ratios, while liquidity remains below the 50-day average. Meyka AI’s forecast model projects a 12-month price of A$0.13594 (about -2.90% versus today), and a monthly projection of A$0.12. That mix produces a cautious view: upside from product traction exists, but execution risk is material. Our Meyka AI grade is B (HOLD), which frames BRN.AX as a speculative, technology-growth exposure best sized for investors who accept revenue execution risk. Keep an eye on Akida commercial updates and any guidance revisions; they will likely drive the next meaningful move in price. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.